EVG.L Regulatory News (EVG)

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Result of General Meeting

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that all resolutions were duly passed at the General Meeting held earlier today.

The General Meeting follows the announcement on 8 December 2017 which gave details of a placing of 19,166,667 new ordinary shares of 0.25p each ("Placing Shares") in the Company at a price of 12p per ordinary share (the "Placing") to raise £2.3 million (before expenses). The Placing is now unconditional.

Application has been made for the Placing Shares to be admitted to trading on AIM which is expected to occur at 8.00 a.m. tomorrow, 29 December 2017.

Total Voting Rights

Following Admission the Company's issued share capital will comprise 93,276,858 ordinary shares with voting rights. The figure of 93,276,858 ordinary shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Market soundings, as defined in MAR, were taken in respect of the proposed fundraise with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/